Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Amendment: Patient Survival Rates in Myelodysplastic Syndrome Following Azacitidine Treatment

  • By

  • Kanticha Thammagul

  • Suppalux Limpiwattakee

  • Pichika Chantrathammachart

  • Teeraya Puavilai

  • Suporn Chuncharunee

  • Pimjai Niparuck

  • September 26, 2026

Share

Clinical Report: Amendment: Patient Survival Rates in Myelodysplastic Syndrome Following Azacitidine Treatment

Background

Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by ineffective hematopoiesis and a risk of progression to acute myeloid leukemia.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

  • The author name Suppalux Limpiwattakee was incorrectly published as Suppalux Limpiwakee.
  • The correction has been officially noted in the publication of the original article.
  • Related studies continue to explore the efficacy of azacitidine in various MDS contexts.

Clinical Implications

Clinicians should ensure they reference the corrected author name in any discussions or citations of the original article. This correction highlights the importance of accuracy in scientific communication.

Conclusion

The correction of the author name is a reminder of the importance of precision in medical literature. Continued research into azacitidine's role in MDS treatment is essential for improving patient outcomes.

Related Resources & Content

  1. BMC Cancer, 2026 -- Amendment: Patient Survival Rates in Myelodysplastic Syndrome Following Azacitidine Treatment
  2. ASCO Publications — Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
  3. ASCO Publications — Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
  4. The ASCO Post — Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
  5. Blood Cancer Journal — Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
  6. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
  7. Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS) | Blood | American Society of Hematology
  8. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study | Journal of Clinical Oncology
  9. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Original Source(s)

Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

  • by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

  • September 26, 2026

Related Content

Correction: Lessons Learned From Implementing a Culturally Tailored Virtual Support Program for Asian American Breast Cancer Survivors With Pain and Depression

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min
MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer

  • September 24, 2026

  • 3 min